By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Taiho Pharmaceutical Company Ltd. 

1-27 Kandanishiki-cho

Chiyoda-ku  Tokyo  101-8444  Japan
Phone: N/A Fax:



Company News
Taiho Pharma Forms Venture Arm in California to Foster Cancer Biotech Start-ups 5/10/2016 6:21:18 AM
Taiho Pharma Release: Patients With Advanced Metastatic Colorectal Cancer In Europe Now Have New Treatment Option As LONSURF (Trifluridine/Tipiracil) Receives EU Approval 4/28/2016 6:10:15 AM
Taiho Pharma's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Phase III TERRA Study In Asian Patients With Refractory Metastatic Colorectal Cancer 4/1/2016 7:53:53 AM
Servier, Taiho Pharma Strike $130 Million+ Cancer Pact 6/15/2015 6:15:11 AM
Taiho Pharmaceutical Submits TAS-102 Marketing Authorisation Application To The European Medicines Agency For The Treatment Of Refractory Metastatic Colorectal Cancer 3/2/2015 6:49:50 AM
Taiho Pharmaceutical Invests US $30 Million In Remiges Biopharma Fund, LP 7/23/2014 11:16:21 AM
Taiho Pharmaceutical's Lonsurf® (Trifluridine And Tipiracil Hydrochloride) Tablets Approved In Japan For Treatment Of Advanced Metastatic Colorectal Cancer 3/24/2014 6:32:25 AM
Response Genetics, Inc. Renews Agreement With Taiho Pharmaceutical to Provide Molecular Analyses for Cancer 7/17/2013 9:28:54 AM
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102 2/27/2013 9:32:07 AM
Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102 5/31/2012 12:28:08 PM